Dompé Presents Phase II Clinical Trial Results for Ladarixin in New-Onset Type 1 Diabetes at the American Diabetes Association’s Scientific Sessions
- Monday, June 15, 2020, 7:35
- PR Newswire
- Add a comment
MILAN and SAN MATEO, California, June 15, 2020 /PRNewswire/ — Dompé Farmaceutici S.p.A and Dompé U.S. Inc., (collectively Dompé) announced topline Phase 2 clinical trial (MEX0114) results for its investigational CXCR1/2 inhibitor, ladarixin, in patients with new-onset type 1 diabetes…
About the Author
admin has written 21009 stories on this site.